PMID

Data

Article Title

Organization

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.

University of Nebraska Medical Center

Discovery of potent and bioavailable GSK-3beta inhibitors.

Roche Palo Alto

A quantitative analysis of kinase inhibitor selectivity.

Ambit Biosciences

Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Ambit Biosciences

From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.

University of Illinois At Chicago

Discovery of a Dual Tubulin and Neuropilin-1 (NRP1) Inhibitor with Potent In Vivo Anti-Tumor Activity via Pharmacophore-based Docking Screening, Structure Optimization, and Biological Evaluation.

China Pharmaceutical University

Discovery of Novel

Shenyang Pharmaceutical University

CDK9 inhibitors in cancer research.

Nankai University

2-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents.

Hunan University of Science and Technology

Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.

Hefei University of Technology

Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.

University of Louisiana At Lafayette

Development and Therapeutic Potential of NUAKs Inhibitors.

University of Science and Technology (Ust)

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.

Astrazeneca

Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents.

Chengdu University

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.

University of South Australia Cancer Research Institute

Carbocyclic sulfone RORγ modulators

Bristol-Myers Squibb

Pharmacological characterization of the human ionotropic glutamate receptor subtype GluR3 stably expressed in mammalian cells.

Sibia Neurosciences